Alkermes stock skidded Monday on the back of mixed results for its experimental narcolepsy treatment, an orexin agonist.

Alkermes outlined plans to move its NT1 drug candidate, alixorexton, into phase 3 after posting results from the midstage ...

The appeal of a drug-patent dispute that allowed patent owner Alkermes PLC to keep $65.6 million in allegedly improper ...

Alkermes’ investigational drug helped people with a type of narcolepsy stay awake during the day in a mid-stage trial.

Ireland-based Alkermes has announced positive topline results from the randomized double-blind treatment period of the ...

Alkermes' alixorexton met key endpoints in a Phase 2 trial for narcolepsy type 1, showing strong efficacy and tolerability ...

The market expects Alkermes (ALKS) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook is ...

Part of a class of therapies that boost “orexin” proteins, the drug just scored positive results in a Phase 2 trial. Analysts have guessed it could ultimately generate billions in sales.

A race to develop a new class of drugs could transform treatment for patients with narcolepsy — as well as for patients with ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $40.67, a high estimate of $45.00, and a low estimate of $33.00. This upward trend is evident, with the ...

Alkermes expects that revenue for full-year 2021 will be between $1.1 billion and $1.17 billion. It anticipates GAAP loss per share of $0.53 to $0.78, with adjusted non-GAAP EPS between $0.37 and ...

The stock price of Alkermes, a biopharmaceutical company focused on neuroscience and oncology, has seen a rise of around 16% over the last twenty-one trading days, and it is up a solid 91% over ...